Company · CIK 0001159036 · SIC 2836 — Biological Products, (No Diagnostic Substances) · Nasdaq
HALOZYME THERAPEUTICS, INC. · HALO
Insider activity reported against this company. All insider holders · On EDGAR ↗
Reported at this company — common stock
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 16, 2026 SForm 4 → | Sep 17, 5:19 pm EDT | Matthew L. PosardDirector | 18,996 | $107.74 | $2,046,581 | 58,839 | −24.4% | 10b5-1 |
| Sep 9, 2026 SForm 4 → | Sep 11, 8:35 pm EDT | Helen TorleyPRESIDENT AND CEO, Director | 60,000 | $107.28 | $6,436,711 | 767,780 | −7.25% | 10b5-1 |
| Sep 9, 2026 MForm 4 → | Sep 11, 8:35 pm EDT | Helen TorleyPRESIDENT AND CEO, Director | 60,000 | $18.41 | $1,104,600 | 787,780 | — | 10b5-1 |
| Sep 1, 2026 AForm 4 → | Sep 2, 4:59 pm EDT | Dannielle AppelhansDirector | 1,161 | — | — | 1,161 | — |
Reported at this company — derivatives (options, RSUs, warrants)
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 9, 2026 MForm 4 → | Sep 11, 8:35 pm EDT | Helen TorleyPRESIDENT AND CEO, Director | 60,000 | $18.41 | $1,104,600 | 81,552 | — | 10b5-1 |
| Sep 1, 2026 AForm 4 → | Sep 2, 4:59 pm EDT | Dannielle AppelhansDirector | 1,778 | — | — | 1,778 | — |